Neural stem cell transplantation in patients with progressive multiple sclerosis: an open-label, phase 1 study
暂无分享,去创建一个
L. Leocani | M. Sormani | A. Falini | V. Martinelli | G. Comi | E. Pagani | G. Martino | M. Rocca | G. Matera | M. Battaglia | F. Ruffini | R. Furlan | L. Moiola | A. Andolfo | F. Ciceri | L. Ottoboni | M. Bacigaluppi | L. Storelli | P. Panina-Bordignon | M. Radaelli | P. Vezzulli | G. Gaipa | L. Vago | G. Scotti | E. Brambilla | R. Greco | D. Belotti | D. Drago | F. Sangalli | C. Magagnotti | D. Capilupo | S. Cesana | Benedetta Cabiati | A. Uglietti | A. Genchi | Marco Bonopane
[1] L. Leocani,et al. Optical Coherence Tomography and Visual Evoked Potentials as Prognostic and Monitoring Tools in Progressive Multiple Sclerosis , 2021, Frontiers in Neuroscience.
[2] C. Soto,et al. Induced Pluripotent Stem Cell-Derived Neural Precursors Improve Memory, Synaptic and Pathological Abnormalities in a Mouse Model of Alzheimer’s Disease , 2021, Cells.
[3] L. Cai,et al. Diversity of Adult Neural Stem and Progenitor Cells in Physiology and Disease , 2021, Cells.
[4] Qilong Cao,et al. Neural stem cell secretome and its role in the treatment of neurodegenerative disorders. , 2020, Journal of integrative neuroscience.
[5] L. Atzori,et al. Multi-Platform Characterization of Cerebrospinal Fluid and Serum Metabolome of Patients Affected by Relapsing–Remitting and Primary Progressive Multiple Sclerosis , 2020, Journal of clinical medicine.
[6] S. Ourselin,et al. Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial , 2020, The Lancet Neurology.
[7] R. Gold,et al. Progressive multiple sclerosis: from pathophysiology to therapeutic strategies , 2019, Nature Reviews Drug Discovery.
[8] Martin H. Pham,et al. Immunosuppressive mechanisms for stem cell transplant survival in spinal cord injury. , 2019, Neurosurgical focus.
[9] Zhibo Wang,et al. Interactive calculator for operating characteristics of phase I cancer clinical trials using standard 3+3 designs , 2018, Contemporary clinical trials communications.
[10] Jeffrey A. Cohen,et al. Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis , 2018, Multiple sclerosis.
[11] Stephen M. Rao,et al. Neuropsychology of Multiple Sclerosis: Looking Back and Moving Forward , 2017, Journal of the International Neuropsychological Society.
[12] G. Comi,et al. Neural precursor cell–secreted TGF-&bgr;2 redirects inflammatory monocyte-derived cells in CNS autoimmunity , 2017, The Journal of clinical investigation.
[13] M. Battaglini,et al. Brain MRI atrophy quantification in MS , 2017, Neurology.
[14] Xavier Lladó,et al. Automated tissue segmentation of MR brain images in the presence of white matter lesions , 2017, Medical Image Anal..
[15] R. Benedict,et al. Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine , 2016, Expert review of neurotherapeutics.
[16] J. A. Kim,et al. Neural stem cell transplantation at critical period improves learning and memory through restoring synaptic impairment in Alzheimer's disease mouse model , 2015, Cell Death and Disease.
[17] K. Alitalo,et al. Vascular Endothelial Growth Factor Receptor 3 Controls Neural Stem Cell Activation in Mice and Humans , 2015, Cell reports.
[18] E. Ruppin,et al. Fumarate induces redox-dependent senescence by modifying glutathione metabolism , 2015, Nature Communications.
[19] Turi O. Dalaker,et al. Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study , 2014, Journal of Neurology, Neurosurgery & Psychiatry.
[20] Thomas Kohlmann,et al. Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis , 2013, BMC Neurology.
[21] M. Horsfield,et al. Gray matter damage predicts the accumulation of disability 13 years later in MS , 2013, Neurology.
[22] G. Comi,et al. iPSC-derived neural precursors exert a neuroprotective role in immune-mediated demyelination via the secretion of LIF , 2013, Nature Communications.
[23] Gerard R. Ridgway,et al. Symmetric Diffeomorphic Modeling of Longitudinal Structural MRI , 2013, Front. Neurosci..
[24] M. Battaglini,et al. Evaluating and reducing the impact of white matter lesions on brain volume measurements , 2012, Human brain mapping.
[25] O. Lindvall,et al. Cross-talk between neural stem cells and immune cells: the key to better brain repair? , 2012, Nature Neuroscience.
[26] Stephen M. Smith,et al. A Bayesian model of shape and appearance for subcortical brain segmentation , 2011, NeuroImage.
[27] D. Gomez-Nicola,et al. Interleukin-15 regulates proliferation and self-renewal of adult neural stem cells , 2011, Molecular biology of the cell.
[28] M. Mann,et al. Andromeda: a peptide search engine integrated into the MaxQuant environment. , 2011, Journal of proteome research.
[29] B. Choi,et al. Granulocyte macrophage-colony stimulating factor shows anti-apoptotic activity in neural progenitor cells via JAK/STAT5-Bcl-2 pathway , 2011, Apoptosis.
[30] David H. Miller,et al. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial , 2010, The Lancet Neurology.
[31] R. Franklin,et al. Stem cell transplantation in multiple sclerosis: current status and future prospects , 2010, Nature Reviews Neurology.
[32] M. A. Horsfield,et al. Rapid semi-automatic segmentation of the spinal cord from magnetic resonance images: Application in multiple sclerosis , 2010, NeuroImage.
[33] S. Nicolis,et al. Sox2 roles in neural stem cells. , 2010, The international journal of biochemistry & cell biology.
[34] Y. Mao-Draayer,et al. Fas activation increases neural progenitor cell survival , 2009, Journal of neuroscience research.
[35] G. Comi,et al. Human neural stem cells ameliorate autoimmune encephalomyelitis in non‐human primates , 2009, Annals of neurology.
[36] J. L. Cox,et al. Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case–control study , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.
[37] M Rovaris,et al. Multimodal evoked potentials to assess the evolution of multiple sclerosis: a longitudinal study , 2006, Journal of Neurology, Neurosurgery & Psychiatry.
[38] E. Snyder,et al. Gene therapy: can neural stem cells deliver? , 2006, Nature Reviews Neuroscience.
[39] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[40] Mitchel S Berger,et al. Neural stem cells and the origin of gliomas. , 2005, The New England journal of medicine.
[41] G. Comi,et al. Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism , 2005, Nature.
[42] K. Boheler,et al. Nestin expression – a property of multi-lineage progenitor cells? , 2004, Cellular and Molecular Life Sciences CMLS.
[43] David J Torgerson,et al. Effect of regression to the mean on decision making in health care , 2003, BMJ : British Medical Journal.
[44] Angelo L. Vescovi,et al. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis , 2003, Nature.
[45] A I Saeed,et al. TM4: a free, open-source system for microarray data management and analysis. , 2003, BioTechniques.
[46] Stephen M. Smith,et al. Accurate, Robust, and Automated Longitudinal and Cross-Sectional Brain Change Analysis , 2002, NeuroImage.
[47] Mart Saarma,et al. The GDNF family: Signalling, biological functions and therapeutic value , 2002, Nature Reviews Neuroscience.